{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:01:59Z","timestamp":1782975719307,"version":"3.54.5"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000063","name":"Office of Dietary Supplements","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000063","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Metastatic uveal melanoma (mUM) is a rare, aggressive malignancy with limited therapeutic options in the metastatic setting. Tebentafusp (IMCgp100) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC), targeting gp100 in HLA-A*0201+ patients. Tebentafusp has demonstrated an overall survival (OS) benefit in clinical trials, usually without marked radiographic tumor regression. We describe a mUM patient who was treated with tebentafusp for more than two years and achieved durable stable disease on imaging but passed away due to sudden cardiac death. Autopsy examination revealed extensive tumor necrosis and dense immune cell infiltration within metastatic liver lesions with minimally viable tumor, providing direct evidence of robust immune activation in the tumor microenvironment. This case highlights the potential for T cell bispecifics to induce profound anti-tumor effects that are not fully captured by conventional radiographic assessment, underscoring the need for integrated clinical, pathologic, and imaging evaluation in this setting.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1864115","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:34:19Z","timestamp":1782970459000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Durable stable disease and immune activation in metastatic uveal melanoma treated with tebentafusp: case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Parham","family":"Habibzadeh","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pittsburgh Medical Center","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushri","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Hurd","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rose","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Bednarz","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana G.","family":"Najjar","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center","place":["Pittsburgh, PA, United States"]},{"name":"Division of Malignant Hematology and Oncology, Department of Medicine, University of Pittsburgh","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center","place":["Pittsburgh, PA, United States"]},{"name":"Division of Malignant Hematology and Oncology, Department of Medicine, University of Pittsburgh","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arivarasan","family":"Karunamurthy","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center","place":["Pittsburgh, PA, United States"]},{"name":"Division of Dermatopathology, Department of Dermatology, University of Pittsburgh","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diwakar","family":"Davar","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center","place":["Pittsburgh, PA, United States"]},{"name":"Division of Malignant Hematology and Oncology, Department of Medicine, University of Pittsburgh","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaophthalmol.2018.2466","article-title":"Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma","volume":"136","author":"Lane","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B2","first-page":"30","volume-title":"Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma","author":"Ciernik","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, A TCR\/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41467-025-57470-w","article-title":"Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer","volume":"16","author":"G\u00fc\u00e7","year":"2025","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1513","article-title":"Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients","volume":"31","author":"Sato","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e70047","DOI":"10.1111\/pcmr.70047","article-title":"Prognostic and Predictive Value of ctDNA for Metastatic Uveal Melanoma: A Systematic Review and Meta-Analysis","volume":"38","author":"Noronha","year":"2025","journal-title":"Pigment Cell Melanoma Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8851","DOI":"10.1038\/s41467-024-53145-0","article-title":"Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp","volume":"15","author":"Rodrigues","year":"2024","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-2274","article-title":"Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma","volume":"32","author":"Ramelyte","year":"2026","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1864115\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:34:20Z","timestamp":1782970460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1864115\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":10,"alternative-id":["10.3389\/fimmu.2026.1864115"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1864115","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1864115"}}